Healthcare / BiotechnologyShanghai
$14.09
+0.34 (+2.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $203.0M · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
35.2x
↑EV/EBITDA
15.5x
↑ROE
6.3%
↑Gross Margin
42.5%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.7%
FCF CAGR
+9.1%
FCF margin
5.1%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.21B · net income $166.9M · FCF $112.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.21B | $2.21B | $2.11B | $2.00B | $1.93B |
| Net Income | $166.9M | $166.9M | $196.8M | $178.1M | $177.2M |
| EBITDA | $343.8M | $343.8M | $385.2M | $361.9M | $343.0M |
| EPS | 0.41 | 0.41 | 0.48 | 0.44 | 0.44 |
| Gross Margin | 42.5% | 42.5% | 43.7% | 42.7% | 44.3% |
| Operating Margin | 8.7% | 8.7% | 10.7% | 10.0% | 12.6% |
| Net Margin | 7.6% | 7.6% | 9.3% | 8.9% | 9.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 |
| Current Ratio | 2.62 | 2.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $112.7M | $112.7M | $203.0M | $217.5M | $86.7M |
| Returns | |||||
| ROE | 6.3% | 6.3% | 7.9% | 7.2% | 9.0% |
| Valuation | |||||
| P/E | 35.23 | 35.23 | 24.73 | 48.45 | 68.80 |
| EV/EBITDA | 15.49 | 15.49 | 11.74 | 22.01 | 33.21 |
| P/B | 2.16 | 2.16 | 1.95 | 3.51 | 6.21 |
| Growth & Yield | |||||
| Revenue Growth | 4.7% | 4.7% | 5.5% | 4.0% | — |
| EPS Growth | -14.6% | -14.6% | 9.1% | 0.0% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
45.0%
EPS terminal req.
$1.25
Spread vs growth
-59.6%
5Y implied EPS CAGR
29.8%
EPS terminal req.
$1.51
Spread vs growth
-44.4%
10Y implied EPS CAGR
19.5%
EPS terminal req.
$2.44
Spread vs growth
-34.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.0%
Start / end P/E
28.8x → 35.3x
EPS bridge
0.48 → 0.41
Residual
-3.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.